Precigen Inc. Stock
Your prediction
Precigen Inc. Stock
Precigen Inc. shows a slight decrease today, losing -€0.040 (-0.830%) compared to yesterday.
Pros and Cons of Precigen Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Precigen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Precigen Inc. | -0.830% | -2.092% | -8.235% | 252.675% | 26.078% | 286.777% | 3.129% |
| Mighty River Power Ltd | 0.000% | 0.000% | 2.484% | 8.553% | 5.769% | -6.780% | -12.698% |
| A2A SpA | -0.650% | -0.517% | 1.449% | 5.239% | 0.566% | 35.802% | 27.483% |
| CEMIG ADR | -0.530% | 0.000% | 1.081% | 21.429% | 9.357% | -19.397% | 24.667% |
News
What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?
On July 1, 2026, Precigen (NASDAQ:PGEN) Chief Financial Officer Harry Thomasian Jr. reported the sale of 200,000 shares of common stock in multiple open-market transactions between June 29 and July
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
Harry Thomasian Jr. Chief Financial Officer of Precigen (NASDAQ:PGEN), reported the sale of 41,884 shares of common stock on May 28, 2026, as disclosed in the SEC Form 4 filing.
Transaction value
Precigen Q1 Earnings Call Highlights
Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025
